期刊文献+

重组人ω-干扰素在金黄地鼠和Wistar大鼠体内的组织分布和排泄 被引量:2

Tissue Distribution and Excretion of Recombinant Human Interferon-ω in Golden Hamsters and Wistar Rats
暂未订购
导出
摘要 目的:为进一步的临床试验提供重组人ω-干扰素(rhIFN-ω)的分布和排泄试验数据。方法:用125I同位素示踪法结合三氯醋酸(TCA)沉淀法测定各主要器官组织的总放射性浓度和酸沉淀部分放射性浓度,获得rhIFN-ω的尿粪排泄和胆汁排泄数据。结果:各主要器官组织的总放射性浓度AUC0-4h排序由大到小依次为:尿、胸腺、胆囊、膀胱、肾、肾上腺、肠内容物、肠淋巴结、空肠、肺脏、血清、卵巢、脾、肝、肌肉、心脏、骨髓/股骨、睾丸、脂肪、脑。皮下注射125I-rhIFN-ω后48h尿和粪的累计排出量分别达到注入放射量的87.9%±2.8%和4.0%±1.6%,尿粪合计排出量占注入放射性量的91.9%±2.1%,而皮下注射125I-rhIFN-ω后20h内胆汁排泄放射性量占注入放射性量的3.34%。结论:rhIFN-ω在泌尿系统分布比较高,与血清蛋白结合比较少,在脑、脂肪和肌肉等组织的药物浓度最低。rhIFN-ω主要以尿的形式排泄。 Objective: To provide experimental information on the metabolism of recombinant human interferon-ω(rhlFN- ω) necessary for subsequent clinical trials. Methods: ^125I-rhOFN-ω was prepared by iodogen method. Tissue distribution and urinary, fecal, biliary excretion profiles of ^125I-rhIFN-ω in golden hamsters and Wistar rats were demonstrated by TCA precipitation and secHPLC method. Results: In order of total radioactivity concentration in organs/tissues for rhIFN-ω, it showed that urine〉thymus〉cholecyst〉bladder〉kidney〉adrenal gland〉intestinal contents〉lymphnodes〉jejunum〉lung〉serum〉ovary〉spleen〉liver〉muscles〉heart〉bone marrow〉testicle〉fat〉brain. Approximately 87.9%±2.8% or 4.0%±1.6% of the total administered radioactivity was recovered in urine or feces within 48 h after administration, respectively; while 3.34% into bile within 20 h after administration. Conclusion: The results suggested that ^125I-rhIFN-ω was distributed to organs/tissues rapidly and widely, although the radioactivity was relatively low because of rapid excretion. Urinary route was the dominant excretion one.
出处 《生物技术通讯》 CAS 2007年第3期457-459,共3页 Letters in Biotechnology
基金 国家高技术研究发展计划项目(2003AA208220和2003AA2Z347B)
关键词 重组人 ω-干扰素 组织分布 排泄 recombinant human interferon-ω tissue distribution excretion
  • 相关文献

参考文献11

  • 1De Maeyer E,De Maeyer-Guignard J.Type 1 interferon[J].Intern Rev Immunol,1998,17:53
  • 2Roberts RM,Liu L,Guo Q,et al.The evolution of the type Ⅰ interferons[J].J Interferon Cytokine Res,1998,18:805
  • 3Pestka S.The interferon receptors[J].Semin Oncol,1997,24(3 supply 9):S9-18
  • 4Meager A,Gaines Das R,Zoon K,et al.Establishment of new and replacement World Health Organization International Biological Standards for human interferon alpha and omega[J].Immunol Methods,2001,257:17
  • 5Bekisz J,Schmeisser H,Hernandez J,et al.Human interferons alpha,beta and omega[J].Growth Factors,2004,22:243
  • 6Adolf GR.Monoclonal antibodies and enzyme immunoassays specif-ic for human interferon(IFN) omega 1:evidence that IFN-omega 1is a component of human leukocyte IFN[J].Virology,1990,175(2):410
  • 7Oritani K,Kincade PW,Zhang C,et al.Type I interferons and limitin:a comparison of structures,receptors,and functions[J].Cytokine Growth Factor Rev,2001,12:337
  • 8Adolf GR.Human interferon omega-a review Austria[J].Mult Scler,1995,1(Suppl 1):44
  • 9Hagelstein J,Kist A,Stremmel W,et al.Antiviral potential of interferon-omega on hepatitis B virus replication in human hepatoma cells[J].Arzneimittelforschung,1998,48:343
  • 10Tiefenthaler M,Geisen F,Schirmer M,et al.A comparison of the antiprolfferative properties of recombinant human IFN-alpha 2 and IFN-omega in human bone marrow culture[J].J Interferon Cytokine Res,1997,17:327

同被引文献17

  • 1卞丽红,梅兴国,章扬培.新一代PEG在修饰抗原和药物缓释中的应用[J].生命科学,2004,16(5):296-300. 被引量:5
  • 2胡永祥,牛津梁,张文博,高林.聚乙二醇修饰药物技术的研究进展[J].中国生化药物杂志,2004,25(6):369-373. 被引量:12
  • 3肖淑华,魏广力,刘昌孝.多索茶碱在大鼠的组织分布和排泄[J].中国临床药理学与治疗学,2005,10(11):1215-1218. 被引量:3
  • 4Davis E F. Enzyme polyethylene glycol adducts: modified enzymes with unique properties[J]. Enzyme Eng, 1978(4) : 169-- 173.
  • 5Bailon P, Berthold W. Polyethylene glycol conjugated pharmaceutical proteins [J]. Pharm Sci Technol Today, 1998 (1) : 352.
  • 6Kozlowski A, Harris J M. Improvernents in protein PEGylation: pegylated interferons for treatment of hepatits C [J]. J Control Release,2001,72 : 21.
  • 7Mehvar R. Modulation of the pharmacokineties and pharmacodynamics of proteins by polyethylene glycol conjugation [J]. J Pharm Pharmaceut Sci, 2000(3) : 125.
  • 8Fraker P J, Speck J C. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6--tetrachloro -- 3a, 6a-- diphrenyl-- glycoluril[J]. Biochem Biophys Res Commun, 1978 (4) : 849.
  • 9Zhou K, Zheng X Q, Xu H M, et al. Studies of polyethylene glycol modification of HM-3 polypeptides [ J ]. Bioconjugate Chemistry, 2009,20:932.
  • 10Xu H M, Yin R T, Wang Y, et al. An RGD-modified endostatinderived synthetic peptide shows antitumor activity in vivo [ J ]. Bioconjugate Chemistry,2008,19(10) : 1980.

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部